SG Americas Securities LLC Sells 17,273 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

SG Americas Securities LLC reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,180 shares of the company's stock after selling 17,273 shares during the period. SG Americas Securities LLC's holdings in Neurocrine Biosciences were worth $946,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Rice Hall James & Associates LLC lifted its stake in Neurocrine Biosciences by 195.5% in the first quarter. Rice Hall James & Associates LLC now owns 206,755 shares of the company's stock worth $19,383,000 after purchasing an additional 136,782 shares during the last quarter. HighTower Advisors LLC grew its holdings in Neurocrine Biosciences by 48.8% in the first quarter. HighTower Advisors LLC now owns 5,745 shares of the company's stock worth $544,000 after purchasing an additional 1,883 shares during the period. PNC Financial Services Group Inc. grew its holdings in Neurocrine Biosciences by 27.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,150 shares of the company's stock worth $296,000 after purchasing an additional 684 shares during the period. Acadian Asset Management LLC purchased a new stake in Neurocrine Biosciences in the first quarter worth about $27,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Neurocrine Biosciences by 39.1% during the first quarter. Dimensional Fund Advisors LP now owns 417,604 shares of the company's stock valued at $39,148,000 after buying an additional 117,422 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Up 2.5 %

NBIX stock traded up $3.46 during mid-day trading on Monday, hitting $141.38. 995,764 shares of the company were exchanged, compared to its average volume of 876,657. The firm has a market capitalization of $14.07 billion, a P/E ratio of 56.99, a PEG ratio of 0.88 and a beta of 0.25. The business has a fifty day simple moving average of $137.28 and a 200-day simple moving average of $124.80. Neurocrine Biosciences, Inc. has a 12-month low of $89.04 and a 12-month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analysts' expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The firm's revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.88 earnings per share. Research analysts predict that Neurocrine Biosciences, Inc. will post 4.88 EPS for the current year.

Insider Transactions at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 200 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $140.00, for a total transaction of $28,000.00. Following the completion of the sale, the insider now owns 7,507 shares in the company, valued at approximately $1,050,980. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock in a transaction on Monday, March 11th. The shares were sold at an average price of $140.00, for a total value of $28,000.00. Following the transaction, the insider now directly owns 7,507 shares of the company's stock, valued at approximately $1,050,980. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David W. Boyer sold 456 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total transaction of $64,733.76. Following the completion of the transaction, the insider now directly owns 4,894 shares in the company, valued at $694,752.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 369,055 shares of company stock worth $49,891,073. 4.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

NBIX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. Citigroup decreased their price target on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a "neutral" rating on the stock in a research report on Thursday, February 8th. Stifel Nicolaus increased their price target on shares of Neurocrine Biosciences from $141.00 to $144.00 and gave the stock a "buy" rating in a research report on Monday, December 18th. Barclays raised their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an "overweight" rating in a research report on Tuesday, January 23rd. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a research report on Tuesday, December 12th. They set a "buy" rating and a $136.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $137.92.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.